MICROBIOME R&D
AND BUSINESSCOLLABORATIONCONGRESS

Organised by:

5-6 MARCH 2025
WYNDHAM GRANDZHAOQING
DOWNTOWN

WWW.GLOBAL-ENGAGE.COM

Co-hosted with:

Hello & Welcome
Welcome to Global Engage’s inaugural microbiome event in China, Microbiome
R&D and Business Collaboration Congress, taking place in-person on the 5th and6th of March 2025 at Wyndham Grand Zhaoqing Downtown, Zhaoqing, China.
Co-hosted with the Handsome Investment Group, this edition is an excellent
platform for researchers and product developers to gain knowledge and explore
strategies to turn discoveries into products. It aims to connect the community
with investors for commercialization support and provides networking
opportunities.
Running on multiple tracks, this conference will showcase unique areas ofscientific and business developments in the skin microbiome and microbiome
spaces. Key thought leaders will share the latest cutting-edge research, emerging
technologies, commercial interest, product development, and regulatory & claim
considerations.
Attend this conference to learn from leading scientists, showcase research, andexplore industry partnerships and funding. It is an event of utmost importancethat you should not miss.
We look forward to seeing you in Zhaoqing, China!
With warm wishes,

Wen Fang Woo
Conference Producer - ASIA

MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

About the Event
Conference synopsis
SKIN MICROBIOME
Skin microbiome & cosmeceuticals
Skin health, wellbeing, andmicrobiome-associated skin disease
Regulatory landscapes & consumer
insights
Skin immunology
Latest advances on mapping andprofiling technologies
Role of skin microbiome in precision
healthAging
Hair & scalp
Wound healing

MICROBIOME
Gut microbiome in health & disease
Beyond gut & women’s health
Microbiome translational medicine
Microbiome therapeutics &regulatory & commercialisation
Microbiome & cancer
Microbiome data & tools
Microbiome & pro/pre/postbiotics
Personalised nutrition and HMO &infantPoster Presentations
Whether looking for funding, job opportunities or simply wanting to share your work witha like-minded and focused group, poster presentations are an excellent way to join theheart of the congress. Poster presentations are actively encouraged at this event and assuch registered academic, industry, and start-up delegates are invited to present 1
poster each for free.
Poster competition
Six poster winners will each receive a cash prize worth USD 500. Two exceptional entries
among the six will be selected for a 15-minute speaking position on the program.
Representatives from solution provider organisations or experts already speaking on the
program are ineligible to enter the competition but are welcome to present posters at
the meeting as normal.
Flash talks
Three 5-minute flash talks are allocated for industry and start-up companies to present
an overview of their research poster.
Submission instruction
Poster competition/ presentation abstract submission deadline is on 27th January 2025.
Download poster presentation/competition form HERE
Contact: haley@global-engage.com for more inquiries

MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

About the Event
Registration:
To register, please visit our website or contact Dhevindran at: Dhevin@global-engage.com

Media Partners:

Official conference/hotel venue:
Wyndham Grand Zhaoqing Downtown
No.13, Xinghu Road, Duanzhou District,Zhaoqing, Guangdong, China
肇庆市七星岩温德姆至尊酒店
中国广东省肇庆市端州区星湖大道五段13号

MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

Our Speakers
MARC GÜELLICREA Research Professor,
Pompeu Fabra University

MOHD HAFIZ ARZMI
WAI-KAY SETO

Clinical Professor,
The University of Hong Kong

Associate Professor,
International Islamic University
MalaysiaJIA XUQI SU

Assistant Professor(Research), Chinese Universityof Hong Kong

Senior Scientist II, Singapore
Institute for Clinical Sciences,
A*STARAARTHI RAVIKRISHNANWEILIAN HUNG

Scientist, Genome Institute ofSingapore (GIS), A*STAR

JODI WOAN-FEI LAW

Professor and CEO, Yonsei
University College of Medicine and
BioMe Inc

Director of Probiotics
Research Center, Yili
Innovation Center

Assistant Professor, Universityof Nottingham Ningbo

ANNALISA TERRANEGRA
Principal Investigator,
Sidra Medicine

SANG SUN YOONSEBASTIAN SCHIDMT
Principal Investigator,
University College Cork

HONGWEI ZHOU

Director, Zhujiang Hospital

ALBERT DASHICSO & Co-Founder,
Sequential

XIAOQUAN SU

Professor, Qingdao University

LAWRENCE WEISSCEO, Symbiome

SENIOR REPRESENTATIVEJOHN COMMON

Deputy Executive Director andProfessor of Cutaneous
Inflammation and Microbiome,
A*STAR Skin Research Labs andNewcastle University

P&G

SENIOR REPRESENTATIVE

DanoneSIAM POPLUECHAIAssociate Professor, Mae FahLuang University

SENIOR REPRESENTATIVE

Handsome Investment GroupERIC HUANG CHUN-MING

Chief Scientific Advisor, Yunneng
Biotechnology Co., Ltd

MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

Wednesday, Mar 5th, 2025

Agenda0800-0830

Registration & Morning Coffee

0830-0835

Global Engage & Handsome Investment Group Welcome Address
Chairperson:

0835-0905

Keynote Presentation
JOHN COMMON

Deputy Executive Director and Professor of Cutaneous Inflammation and Microbiome, A*STAR Skin Research Labs and Newcastle University

THE SKIN MICROBIOME IN CHRONIC INFLAMMATORY SKIN DISEASESThe skin is home to millions of bacteria, fungi and viruses that make up the complex communities of our skin microbiota. The composition of these microbialcommunities differ depending on biogeographical skin location and can remain stable for years. Technological advances in sequencing have allowed researchers
to investigate resident microbial population at high resolution providing valuable insights into disease pathogenesis. These culture-independent investigations of
the skin microbiome is revealing a much more complex picture of the contribution of species and stains to disease pathogenesis and severity. One of the largest
disruptors of our skin microbiome is the occurrence of inflammatory skin diseases such as atopic dermatitis and ichthyosis. With atopic dermatitis being adisorder that effects 1 in 5 children, studies of the skin microbiome is particularly important when considering the paediatric phase of life. Recent studies areunraveling the mechanisms of host-microbe interplay at the skin barrier. Understanding the microbes and their collective contribution to skin health is important
for the development of novel therapeutic approaches and interventions for improved relationships with our closest neighbours.
0905-0935

Keynote Presentation
INVITATION OUT

0935-1005

Solution Provider Presentation
For sponsorship opportunities, please contact reuben@global-engage.com

1005-1055

Morning Refreshments I Poster Presentations I 1-2-1 Meetings
MICROBIOTA & SKIN DISEASE
Chairperson:1055-1115

MICROBIOME DATA & TOOLS
Chairperson:

MAURICE VAN-STEENSEL (Reserved)

Professor of Dermatology and Skin Biology, Lee Kong Chian School of Medicine,
Nanyang Technological University

THE CASE FOR SELECTIVE MICROBIOME CONTROLQI SUAssistant Professor (Research), The Chinese University of Hong Kong

GUT MICROBIOME MEETS ARTIFICIAL INTELLIGENCE

Agenda1055-1115

1115-1135

Wednesday, Mar 5th, 2025
In my talk, I will try to make the case for the importance of selective
microbiome control. By that I mean precise removal of species from a bacterial
microbiome with the goal of rebalancing it. This notion is based on the growing
realisation that for correct function and interaction with the host, amicrobiome needs to have a healthy balance of bacterial species. If one starts
to predominate, as in infection, the balance is disturbed and the normal,
beneficial interaction with the host disrupted. Tissue disease or dysfunction
can result, as for example in acne. Restoring skin health in this condition isdifficult to achieve with non-selective bacterial control, for instance with
antiseptics such as benzoylperoxide. More precise interventions are needed.

MARC GÜELLICREA Research Professor, Pompeu Fabra University

MODULATING THE HOST SKIN USING THE SKIN MICROBIOME
We will present our advancements in transforming Cutibacterium acnes into a
synthetic biology platform tailored for skin applications. Initially, our focus wason leveraging this bacterium to achieve sustained alterations in the skin's
microbiome, utilizing natural variants. The stable environment of its natural
habitat, the sebaceous appendices, provides a robust foundation for persistentbioengineering. Our efforts led to notable successful colonization andinteresting therapeutic effects.
In recent years, our work has expanded to include the development of robust
tools for the precise genetic manipulation of C. acnes. This includes a variety ofsynthetic biology components, circuit designs, and methodologies for genetic
modification. Notably, we have developed several biocontainment approaches
for controlled application of genetically altered bacteria. We have engineered
and characterized the effectiveness of various synthetic functions, such as
sebum regulation, immune system interaction, and sensing.
Our vision is to introduce new functions to human skin by engineering theseendogenous microbes.

Artificial Intelligence (AI) is a powerful tool for gut microbiome. We explored thepotential of AI with its application in the crosstalk between gut dysbiosis andLong COVID. We found that gut microbiome during the acute SARS-CoV-2
infection is related to the emergence of Long COVID after viral clearance, andbased on this we built a regression model that predicts the length of the viral
positive period, a binary model that predicts the risk of Long COVID, a multi-label
model that predicts different symptoms, and a multi-class model that
distinguishes Long COVID from common human diseases. Our series of studies
revealed the significance of AI in understanding the role of gut microbiota in thepathogenesis, diagnosis and therapeutics of Long COVID and provided novel
insights into the potential of gut microbiome-targeted applications for Long
COVID in the post-COVID era.
SEBASTIAN SCHIDMT

Principal Investigator, University College CorkAgenda1135-1150

Wednesday, Mar 5th, 2025
EARLY CAREER RESEARCHER
This session is allocated for early career researchers to showcase theirresearch at this conference. Please contact wenfang@global-engage.com tosubmit your interest

EARLY CAREER RESEARCHERAARTHI RAVIKRISHNAN

Scientist, Genome Institute of Singapore (GIS), A*STAR

GUT METAGENOMES OF ASIAN OCTOGENARIANS REVEALMICROBIAL SPECIES PROMOTING HEALTHY AGING
While rapid demographic changes in Asia are driving the incidence of chronic
diseases related to aging, the limited availability of high-quality in vivo data
hampers our ability to understand complex multi-factorial contributions, including
gut microbial, to healthy aging. Leveraging the availability of a well-phenotyped
cohort of community-living octogenarians in Singapore, we used deep shotgun
metagenomic sequencing to do high-resolution taxonomic and functional
characterization of their gut microbiomes (n=234). Species-level analysis identified
a distinct age-associated shift in Asian gut metagenomes, characterized by areduction in microbial richness, and enrichment of specific Alistipes species (e.g.
Alistipes onderdonkii). Functional pathway analysis confirmed that these changes
correspond to a metabolic switch in aging from microbial guilds that typically
produce butyrate in the gut (e.g. Faecalibacterium prausnitzii, Roseburia
inulinivorans) to alternate pathways that utilize amino-acid precursors. Extending
these observations to key clinical markers helped identify >15 robust gut microbial
associations to cardiometabolic health, inflammation, and frailty, including
potential probiotics such as Parabacteroides goldsteinii and pathogenic species
such as Dialister invisus, highlighting the role of the microbiome as biomarkers andpotential intervention targets for promoting healthy aging.

1150-1210

JODI WOAN-FEI LAWAssistant Professor, University of Nottingham Ningbo

THE GUT-SKIN AXIS: GUT MICROBIOME CONNECTIONS TOATOPIC DERMATITIS (ECZEMA)
Atopic dermatitis (AD) is the most prevalent chronic inflammatory skin disease
that manifests early in life, impacting 15–30% of children and 10% of adults. AD
typically starts in childhood, with 60% of patients <1 year of age developing thedisease. Recent advancements in research have shed light on the intricate
relationship between the gut microbiome and the development of AD, thus,
elucidating the concept of the gut-skin axis. Infancy and childhood are critical
periods for the development of the gut microbiome, which in turn influences

XIAOQUAN SU

Professor, Qingdao University

AgendaWednesday, Mar 5th, 2025
immune system maturation that shapes an individual’s disposition to AD. Thisbidirectional communication highlights the dynamic complexity of the body’s
ecosystem, where perturbations in the gut microbiome can have profound
implications on skin health and disease manifestation. This presentation delves
into the burgeoning field of research investigating the relationships between
the gut microbiome and AD, aiming to understand the underlying mechanisms
and potential therapeutic avenues.

1210-1240

1240-1340

Solution Provider Presentation
For sponsorship opportunities, please contact reuben@global-engage.com

Solution Provider Presentation
For sponsorship opportunities, please contact reuben@global-engage.com

Lunch I Poster Presentations I 1-2-1 Meetings
WOMEN’S & INFANT HEALTH
Chairperson:

1340-1400

1400-1420

PROBIOTICS I PERSONALISED NUTRITION I HMO
Chairperson:

INVITATION OUT
For speaking opportunities, please contact Wen Fang at(Wenfang@global-engage.com)
JIA XU

Senior Scientist II, Singapore Institute for Clinical Sciences, A*STARTHE HUMAN GUT MICROBIOME IN PREGNANCY AND EARLY LIFE:
INSIGHTS FROM THE MULTI-ETHNIC ASIAN COHORTS GUSTOAND S-PRESTO
The gut microbiota plays pivotal roles in regulating host metabolism, immune
response, and mental health. From birth, maternal microbes seed the neonatal
gut, initiating the development of the infant's gut microbiota alongside
physiological maturation. This process is foundational to long-term humanhealth. Pregnancy and early infancy are critical periods characterized by rapid
metabolic, physiological, and immunological changes, highly sensitive to both
intrinsic and extrinsic factors. Understanding the development of the gut
microbiome during these stages can enhance our knowledge of developing
microbiome-targeted interventions to mitigate risks associated with noncommunicable diseases. In her presentation, Dr. Jia Xu will elucidate her recent
findings on several key aspects of microbiome development:

SIMON WANG (Reserved)

Probiotics Lead – Active Living, Fonterra GroupWEILIAN HUNG

Director of Probiotics Research Center, Yili Innovation Center

THE DEVELOPMENT AND APPLICATION OF NATIVE PROBIOTICSTRAINS IN CHINA
In recent years, the overall probiotic fever continues to intensify, and the global
probiotic market is advancing steadily and rapidly. It is anticipated that the global
market scale of probiotics will reach 111.5 billion US dollars by 2030. From the
aspect of the regional market situation, the consumption scale of probiotics in the
Asia-Pacific region holds the highest proportion in the world. The structure of theaging and the young has turned into the main potential battleground for the
future development of probiotics in China. In response to the market andconsumer demands, Yili Probiotic Research Center pools the strength from theupper, middle, and lower reaches of strain research and development, takes theresearch and development of Chinese patented probiotics as the direction, and isdedicated to exploring probiotics that are more suitable for the Chinese people.

Wednesday, Mar 5th, 2025

AgendaChanges in women’s gut microbiome from preconception to post-delivery
and its link with metabolic health;
The colonization of gut microbiome in early life and how various intrinsic
and early-life factors influence their acquisition;
The effects of modern practices on the colonization of beneficial microbes
in the infant gut
1420-1440

SENIOR REPRESENTATIVE
DanoneANNALISA TERRANEGRA

Principal Investigator, Sidra Medicine

THE GUT MICROBIOTA AS BIOMARKER OF CLINICAL OUTCOMES IN
THE CONTEXT OF TYPE 1 DIABETESType 1 diabetes (T1D) is one of the common pediatric diseases in Qatar. In across-sectional study of 102 pediatric T1D patients, we searched for potential
microbial biomarkers of clinical outcomes and explored the role of diet inmodulating the biomarkers. Briefly, the genus Akkermansia, a mucin-degrading
bacterium, was significantly elevated in the Qatari patients with poorly
controlled HbA1c levels (>7.5%) and consuming an Arabic diet. A distinct
microbial signature has been associated with high blood pressure (BP>90th
percentile), characterized by a reduced Bifidobacterium genus. An integrated
analysis of the nutrient intake, gut microbiome, and blood transcriptome
discriminated T1D-obese patients (BMI>95th percentile) from non-diabetic
obese children. These findings show the strong potential of the gut microbiota
as a biomarker of clinical outcomes and will pose the basis for microbiomebased therapies for T1D.

1440-1510

Solution Provider Presentation
For sponsorship opportunities, please contact reuben@global-engage.com

1510-1600

Afternoon Refreshments I Poster Presentations I 1-2-1 Meetings

Solution Provider Presentation
For sponsorship opportunities, please contact reuben@global-engage.com

Chairperson:
1600-1615

Flash Presentations
Three 5-minute flash talks are allocated for industry and start-up companies to present an overview of their research

AgendaWednesday, Mar 5th, 2025

1615-1700

Panel Discussion
COMMERCIALISATION: SCIENCE VERSUS CONSUMERS
Recent advances
Strategies for bringing products to market
Application and regulations
Consumer
Future direction

1705

End of Day 1 I Dinner Reception
All delegates are welcome to join the dinner reception

Agenda
0800-0900

Thursday, Mar 6th, 2025
Registration & Morning Coffee
SKIN MICROBIOME

0900-0930

HUMAN MICROBIOME

Chairperson:

Chairperson:

Keynote Presentation
INVITATION OUT

Keynote Presentation
HONGWEI ZHOU

Director, Zhujiang Hospital

0930-1000

Keynote Presentation
LAWRENCE WEISSCEO, Symbiome

Keynote Presentation
RAVINDER NAGPAL (Reserved)

Director and Assistant Professor, Florida State University

BACK TO HEALTH - AN EVOLUTIONARY BIOLOGY PERSPECTIVE ON
THE SKIN MICROBIOME
Major Points
Metagenomics and metabolomics of the Yanomami skin microbiome.
Functional anatomy of the ancestral skin microbiome.
Translating the ancestral skin microbiome into safe and effective
interventions.
The emerging science of the microbiome is still in its infancy, yet it is the driving
force behind a transformative scientific revolution. What lies ahead will havebroad implications for us as scientists, our companies and academic
institutions, our health, and perhaps our survival. It is worth reflecting on where
we are today, how we got here, what we have learned so far, and the limitationsof our methods and of our vision. I will discuss what we are learning about our
biological past from the microbiota of minimally impacted hunter-gatherers
and how it challenges our deeply held ideas about human health that may
inform our path forward.
1000-1030

Solution Provider Presentation
For sponsorship opportunities, please contact: reuben@global-engage.com

1030-1120

Morning Refreshments I Poster Presentations I 1-2-1 Meetings

Solution Provider Presentation
For sponsorship opportunities, please contact: reuben@global-engage.com

AgendaThursday, Mar 6th, 2025
COMPANY SPOTLIGHT
Chairperson:

1120-1140

MICROBIOME IN HEALTH AND DISEASE - GUT & BEYOND
Chairperson:

SENIOR REPRESENTATIVE
Handsome investment Group

WAI-KAY SETO

Clinical Professor, The University of Hong Kong

THE GUT MICROBIOME AND THE LIVER: THE PRESENT AND THE
FUTUREThe gut microbiome has been linked to many aspects of human health, including
the liver. This talk will review the latest findings on the gut-liver axis, including
the role of the microbiome in liver metabolism, inflammation, and in various
chronic liver diseases, including viral hepatitis, metabolic associated fatty liverdisease, liver cirrhosis and liver cancer. We will also discuss emerging strategies
for manipulating the gut microbiome to promote liver health, such as probiotics,
and fecal microbiota transplantation. The presentation aims to provide acomprehensive overview of this burgeoning field, emphasizing the importance ofunderstanding the gut microbiome's impact on liver health and disease
management.
1140-1200

GRACE PARK (Reserved)
VP R&D, HelloBiome

REDEFINING SKIN TYPES THROUGH AI: MICROBIOME-BASEDSEGMENTATION FOR PRODUCT INNOVATION ANDPERSONALIZATION
The dynamic interplay between the skin microbiome and personal careproducts is multifaceted and intricate. While these products aim to cleanse,
beautify, and protect, they can sometimes disturb the delicate balance of skinmicrobes, leading to dysbiosis. Recognizing the importance of the microbiome's
influence on skin health, our study recruited 1000 participants who completed
detailed skin and lifestyle questionnaires and collected skin microbiome
samples at home. Through a comprehensive analysis, we observed distinct skinmicrobiome profiles, classifying various skin types into clusters based on theirpredominant microbial species, such as Cutibacterium, Corynebacterium,
Staphylococcus, and Streptococcus. Our formulating strategy targeted thesemicroorganisms linked to specific skin conditions within each cluster. Our
method went beyond selecting active ingredients that modify microbial

MOHD HAFIZ ARZMI

Associate Professor, International Islamic University Malaysia

HARNESSING THE POWER OF BIOTICS: INNOVATIONS IN ORALMICROBIOME MANAGEMENT FOR OPTIMAL HEALTH
Probiotics, prebiotics, and postbiotics are revolutionizing oral health care,offering cutting-edge solutions for preventing and managing oral diseases.
Probiotics, composed of live beneficial bacteria, inhibit harmful pathogens,reducing incidences of dental caries, periodontitis, and halitosis. Prebiotics, nondigestible fibers, selectively nourish these beneficial bacteria, fostering a robustand balanced oral microbiome. Postbiotics, the metabolic byproducts ofprobiotics,
exhibitpowerfulantimicrobial,
anti-inflammatory,
andimmunomodulatory properties, further enhancing oral health. This triad of
biotics not only disrupts pathogenic biofilms but also promotes oral tissue
health and systemic immunity. The integration of these biotics into oral careproducts represents a paradigm shift towards natural, holistic, and effective
dental therapies. At this congress, he will present the latest research,technological advancements, and potential applications of probiotics,

Agenda1200-1230
1230-1250

Thursday, Mar 6th, 2025
populations; we carefully adjusted product pH and moisture levels and chose
suitable preservatives and ingredients, crafting bespoke solutions for eachunique skin profile.

prebiotics, and postbiotics, heralding a new era in oral health that is bothscientifically groundbreaking and clinically transformative.

Solution Provider Presentation
For sponsorship opportunities, please contact: reuben@global-engage.com

Solution Provider Presentation
For sponsorship opportunities, please contact: reuben@global-engage.com

ALBERT DASHICSO & Co-Founder, Sequential

SIAM POPLUECHAIAssociate Professor, Mae Fah Luang University

A TRADITIONAL THAI MEDICINE INTERVENTION FOR NCDSTARGETS GUT
Noncommunicable diseases (NCDs) are the primary cause of morbidity andmortality on a global scale. Globally, type 2 diabetes mellitus (T2DM) has
emerged as a significant public health concern. In Thailand, patients with
noncommunicable diseases (NCDs) frequently combine conventional medicine
with traditional Thai medicine. Recent research suggests that metabolic
disorders are influenced by the intestinal microbiota. Numerous studies haveindicated that nutraceutical interventions that enhance the microbiota andinduce clinical improvements in metabolic diseases have expanded significantly.
Mathurameha (MT) is an oral dosage formulation that is utilized to treat patientswith T2DM. It is composed of 26 medicinal plants. In this investigation, the gut
microbiota, bioactive compounds, toxicity, and bioactivities of MT were
investigated using multi-omics analysis. The LC-MS-qTOF analysis of MT
revealed that the metabolites contain phenolic compounds and terpenoids. In
vitro cell culture analysis demonstrated bioactive compounds showed αglucosidase inhibition activity and stimulated the percent of glucose
consumption. An investigation was conducted to examine the impact of MT on
induced diabetic rats and patients with T2DM. The study revealed that MTintervention resulted in a significant reduction in blood glucose levels in bothdiabetic rats and T2DM patients, compared to the control group. In addition, MTinterventions alter the composition of gut flora and fecal metabolites. The
findings indicated that Mathurameha might help reduce blood glucose levels in
T2DM through several mechanisms.

Agenda1250-1310

Thursday, Mar 6th, 2025
ERIC HUANG CHUN-MING

Chief Scientific Advisor, Yunneng Biotechnology Co., Ltd

Senior Representative (Reserved)
P&G

SKIN S. EPIDERMIDIS, RIBOTYPES, PHENOTYPES AND
BIO-ENGINEERING AS THERAPEUTICS
Different subtypes of Staphylococcus epidermidis (S. epidermidis) have been
isolated from various resources in our laboratories. Ribotyping these S.
epidermidis was conducted by deep learning neural network. Phenotyping
these bacterial subspecies were achieved by biological assays in vitro and invivo. Several SCFA-, carotenoids- and/or electrons-producing S. epidermidis
was characterized. To non-genetically modify skin bacteria as bio-therapeutics,
S. epidermidis bacteria were uploaded carotenoids (beta-carotene) on theirmembranes. Provision of external carotenoids to S. epidermidis substantiallyelevate the transcriptional expression of the NDH-2, and promote the electron
production. Inoculation of carotenoid-laden bacteria onto the UV-irradiatedmouse skin significantly diminished reactive oxygen species (ROS),
demonstrating its beneficial effect on combating Redox imbalance. These
carotenoids-laden S. epidermidis bacteria become new therapeutics fortreatment of redox imbalance-associated human disorders such as cancer,
aging, infection and inflammation.
1310-1410

Lunch I Poster Presentations I 1-2-1 Meetings
HAIR & SCALP MICROBIOME I WOUND HEALING

1410-1425

1425-1445

MICROBIOME IN THERAPEUTICS DEVELOPMENT

Chairperson:

Chairperson:

Poster Winner Presentation
Poster winners will receive a cash prize worth USD 500 and a 15-minutespeaking position on the program (eligible for non-vendor authors andregistered delegates only)

Poster Winner Presentation
Poster winners will receive a cash prize worth USD 500 and a 15-minutespeaking position on the program (eligible for non-vendor authors andregistered delegates only)

LOH TENG-HERN TAN (Reserved)

Assistant Professor, University of Nottingham Ningbo

INNOVATIVE WOUND DRESSINGS: USE OF PROBIOTICS FOR
ENHANCED HEALINGThe use of probiotics in wound dressings is emerging as a novel approach in
the field of wound care. Probiotics, with their antimicrobial and anti-

YAN TAN (Reserved)
CEO, XBiome

AgendaThursday, Mar 6th, 2025
inflammatory properties, offer a unique advantage in promoting wound healing
and preventing infections. This presentation delves into the development andapplication of probiotic-infused wound dressings, examining how thesebioactive materials support the healing process. Key mechanisms include thesuppression of pathogenic bacteria, enhancement of the skin's natural
microbiome, and stimulation of tissue regeneration. Clinical trials andexperimental studies demonstrating the effectiveness of probiotic dressings inaccelerating wound closure and improving healing outcomes will be highlighted.
This innovative approach has the potential to revolutionize wound care, offeringa promising alternative to conventional treatments.

1445-1505

Senior Representative (Reserved)
J&J

YONG-LIANG ZHU (Reserved)

CEO & Founder, PrecisionBio Inc

GENETICALLY ENGINEERED BACTERIA FOR THE TREATMENT OF
HYPERURICEMIAHyperuricemia (HUA), i.e. increased serum uric acid (UA) concentration, is acommon problem in clinical practice. It is estimated to occur in approximately
8.9% to 24.4% of the general population. HUA causes gout and it also plays a rolein the pathogenesis of chronic kidney disease, hypertension, cardiovasculardisease and heart failure. Currently treatments of HUA is inadequate as small
molecule drugs in treating gout have severe side effects. We aim to develop live
bacterial therapeutics in the management of HUA. E. coli Nissel 1917 wasengineered to overexpress a fungi uricase. Engineered bacteria showed activity
in breaking down uric acid in vitro. Furthermore, protein structure directed
mutations were made for the uricase to have stronger UA breaking activity. A
xanthine oxidase gene knockout was also carried out to block UA formation inengineered strains. Strains with different combinations of mutant genes andknockout showed different degree of UA lowering activity in in vitro or in vivo
assays. One strain was selected for further development as it strongly lowered
blood uric acid level in huperuricemia model animals.
1505-1525

1525

Senior Representative (Reserved)
UnileverSANG SUN YOON

Professor and CEO, Yonsei University College of Medicine and BioMe Inc

GENETICALLY ENGINEERED BACTERIA FOR THE TREATMENT OF
HYPERURICEMIA

AgendaThursday, Mar 6th, 2025
Hyperuricemia (HUA), i.e. increased serum uric acid (UA) concentration, is acommon problem in clinical practice. It is estimated to occur in approximately
8.9% to 24.4% of the general population. HUA causes gout and it also plays a rolein the pathogenesis of chronic kidney disease, hypertension, cardiovasculardisease and heart failure. Currently treatments of HUA is inadequate as small
molecule drugs in treating gout have severe side effects. We aim to develop live
bacterial therapeutics in the management of HUA. E. coli Nissel 1917 wasengineered to overexpress a fungi uricase. Engineered bacteria showed activity
in breaking down uric acid in vitro. Furthermore, protein structure directed
mutations were made for the uricase to have stronger UA breaking activity. A
xanthine oxidase gene knockout was also carried out to block UA formation inengineered strains. Strains with different combinations of mutant genes andknockout showed different degree of UA lowering activity in in vitro or in vivo
assays. One strain was selected for further development as it strongly lowered
blood uric acid level in huperuricemia model animals.

1525

End of Day 2

Post Conference Event

Tour to Songshan Lake Scipolis
Date: 7th MARCH 2025
Time: 8:00 - 12:00pm (half-day tour)
Transportation: Provided by organizer

Agenda8:00 - 10:30 AM

Depart from Wydham Grand Downtown Zhaoqing hotel toSongshan Lake Scipolis

10:30 - 12:00 PM

Site visit and exchange session

12:00 - 14:00 PM

Lunch

14:00 - 16:30 PM

To Guangzhou Baiyun International Airport

A limited number of seats is available and they will be granted on a first-come-first-served basis.

Songshan Lake Scipolis is situated in the core area of the Dongguan Songshan Lake
Biomedical Industry Base. The venue is affiliated with various service platforms,
enterprise clusters, industry associations, and universities, as well as multiple provincial
and municipal key laboratories and technical research centers. It offer a comprehensive
integration of production, life, and ecology, providing a wide range of professional
services for enterprises and institutions. These services include talent recruitment andtraining, finance and investment support, intellectual property protection, market
channel development and achievement transformation. Additionally the venue cancustomize to high-standard industrial spaces to meet the specific needs of enterprises
and institutions.

MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

Additional Information
Transportation options:

By car/taxi from Guangzhou Baiyun International Airport hotel.
Taxis are abundant and easily accessible from the airport. It takes 1.5 hours toreach the hotel, with the cost ranging from approximately USD42 ~ USD55 per ride.
Car rentals - there are numerous rental car agencies throughout the region, withseveral located at the airport.
By metro/bullet train from Guangzhou Baiyun International Airport
hotel
Disembark Guangzhou East Railway Station from airport T1 (Airport South Station)or T2 (Airport North Station) using metro line 3. The duration is about 37-min, withtrain interval of 7-min.
By taxi, the trip to Guangzhou East Railway Station takes about 40-min.
From Guangzhou East Railway Station, take a bullet train to Zhaoqing East Railway
Station. This journey takes about 30 minutes. The hotel is 27 kilometers from
Zhaoqing East Railway Station.

Shuttle Service:

Shuttle bus will be provided from Guangzhou Baiyun International Airport to theconference hotel. The schedule will be provided closer to event date.

Discover Zhaoqing:
Zhaoqing located in the central‑west part ofGuangdong province, is one of the National
Famous Historical and Cultural Cities and the Top
Tourist Cities of China. Also known as the “capitalof inkstones in China”, Zhaoqing is rich in tourism
resources, where a long tourism corridor has
been developed, with the Xinghu Scenic Area as
the centre and numerous tourist attractions
along Xijiang and Suijiang.
Admire the hundreds of Tang Dynasty
inscriptions decorating the adjacent Seven Star
Crags, check out the rare red-crowned cranes in
Xingu Wetland Park, and see the spectacularwaterfall and Buddhist temple of Qingyun on ahike at Dinghu Mountain.
Discover more
MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

Additional Information
Visa application:
If you are attending from a country requiring a visa, please be sure to apply earlyand complete all required fields. Applications may be denied if necessary
information is not included when submitted. We recommend applying for yourvisa as early as possible.
Learn more

Visa exemption program:
From March 14, 2024 to December 31, 2025, China has decided to implement a
unilateral visa-free policy for ordinary passport holders from twelve countries:
Germany, France, Italy, the Netherlands, Spain, Malaysia, Switzerland, Ireland,
Hungary, Austria, Belgium and Luxembourg. Citizens holding ordinary passports
from the above countries who come to China for business, tourism, family visit
and transit purposes for no more than 15 days can enter China without a visa.
However, it is advisable to confirm visa requirements with your local embassy.
Individuals from the above-mentioned countries who do not meet the conditions
for visa exemption still need to apply for a visa before entering China.
Learn more

Invitation letter:
Please contact haley@global-engage.com to request an invitation letter needed
to begin your visa application process.

MICROBIOME R&D AND BUSINESS COLLABORATION: CHINA

20 20Upcoming Events 24 25
21-22

NOV

2nd Spatial Biology Congress Asia
LKC School of Medicine, NTU, Singapore
Co-hosted with Genome Institute of Singapore, A*STAR

3rd Cell & Gene Therapy Research& Development Congress Asia
Singapore

8-9

MAY

APR

9th Microbiome R&D and Business
Collaboration Congress: Asia
Singapore

Spatial Biology Congress: CHINA

26-27

JUN

Guangzhou, China

10-11

10-11

2nd Single Cell Congress Asia

JUL

Hong Kong

For more information
www.global-engage.com